ArticleOral Ovulation Induction AgentsShapiro, Alice MD; Kashani, Banafsheh MD; Seungdamrong, Aimee MDAuthor Information Dr. Shapiro is a Resident, Dr. Kashani is a Fellow in Reproductive Endocrinology and Infertility, and Dr. Seungdamrong is Clinical Assistant Professor, Department of Obstetrics & Gynecology, Rutgers-New Jersey Medical School, 185 South Orange Ave, MSB E506, Newark, NJ 07103; E-mail: firstname.lastname@example.org. The authors, faculty, and staff in a position to control the content of this CME activity, and their spouses/life partners (if any), have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. The authors have disclosed that the U.S. Food and Drug Administration has not approved the use of tamoxifen, letrozole, and anastrozole for ovulation induction, as discussed in this article. Please consult the product labeling for approved uses. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation on the enclosed answer form, answering at least seven of the 10 quiz questions correctly. This activity expires on September 14, 2018. Topics in Obstetrics & Gynecology: September 15, 2017 - Volume 37 - Issue 13 - p 1-7 doi: 10.1097/01.PGO.0000524396.51472.40 Buy Take the CME Test Metrics © 2017 by Lippincott Williams & Wilkins, Inc.